Related references
Note: Only part of the references are listed.Pharmacogenetic and Germline Prognostic Markers of Lung Cancer
Anne M. Horgan et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Association Between Polymorphisms of ERCC1 and XPD and Clinical Response to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
Fan Li et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial
A. C. Vilmar et al.
ANNALS OF ONCOLOGY (2010)
No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy
Peng Yuan et al.
CANCER BIOLOGY & THERAPY (2010)
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
Howard L. McLeod et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
RRM1 single nucleotide polymorphism-37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
Song Dong et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients
Tomoyoshi Takenaka et al.
LUNG CANCER (2010)
Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients
H. Ueno et al.
BRITISH JOURNAL OF CANCER (2009)
DNA Repair Gene Polymorphisms Predict Favorable Clinical Outcome in Advanced Non-Small-Cell Lung Cancer
Aristea Kalikaki et al.
CLINICAL LUNG CANCER (2009)
Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non-Small-Cell Lung Cancer
Craig Reynolds et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non-Small-Cell Lung Cancer Treated With Carboplatin and Gemcitabine
Bente Holm et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2008)
Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene
Soo-Ok Kim et al.
CLINICAL CANCER RESEARCH (2008)
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin -: Treated advanced non-small cell lung cancer patients
Carmelo Tibaldi et al.
CLINICAL CANCER RESEARCH (2008)
Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer
Gerold Bepler et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway
Laurence Gamelin et al.
CLINICAL CANCER RESEARCH (2007)
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer
Daniela F. Giachino et al.
CLINICAL CANCER RESEARCH (2007)
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
P. Ceppi et al.
ANNALS OF ONCOLOGY (2006)
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy
Thierry Lecomte et al.
CLINICAL CANCER RESEARCH (2006)
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients
R de las Peñas et al.
ANNALS OF ONCOLOGY (2006)
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
T Le Chevalier et al.
LUNG CANCER (2005)
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
W Zhou et al.
CLINICAL CANCER RESEARCH (2004)
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer
D Isla et al.
ANNALS OF ONCOLOGY (2004)
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy
S Gurubhagavatula et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy
JS Ryu et al.
LUNG CANCER (2004)
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway
AK Fukunaga et al.
PHARMACOGENOMICS JOURNAL (2004)
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975
EF Smit et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
